Company registration number 04776118 (England and Wales)
MATRIX CHEMIE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
MATRIX CHEMIE LIMITED
COMPANY INFORMATION
Directors
K Polotnianka
D M Brooke
C Mullaney
Company number
04776118
Registered office
Unit 6 Turnberry Park
Gildersome
Morley
Leeds
LS27 7LE
Auditor
Sumer Auditco Limited
New Chartford House
Centurion Way
Cleckheaton
Bradford
West Yorkshire
BD19 3QB
MATRIX CHEMIE LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Directors' responsibilities statement
4
Independent auditor's report
5 - 7
Statement of comprehensive income
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 22
MATRIX CHEMIE LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The directors present the strategic report and financial statements for the year ended 31 December 2025.

Review of the business

Trading in 2025 was improved on the previous year with turnover and gross margin increasing by 11% and 7% respectively.

 

Challenging trading conditions surrounding foreign currency in some markets remained, but in general have improved significantly.

 

The company continues its commitment to its quality, environment impacts, ethical trading and sustainability. ISO 9001:2015, ISO 14001:2015 accreditations remain in place along with ECOVADIS Silver status.

 

On behalf of the company, we sincerely thank our dedicated team and all customers and suppliers for their great commitment and cooperation, and we look forward to a strong and rewarding 2026.

 

The company has started 2026 with strong performance and anticipates a successful 2026.

 

Principal risks and uncertainties

The Company has carried out an extensive financial risk management analysis, covering aspects such as currency, interest rates & liquidity, credit and market (supply chain and customer base) risks.

 

Currency

A significant proportion of the Company’s turnover is in Euros & US Dollars. Fluctuations in these currencies could affect the financial performance of the business. Forward contracts are taken out and currency swaps are currently undertaken where necessary to mitigate any such risk.

 

Interest rates & liquidity

The Company is well funded and working capital flows are managed via the use of KPI’s within the business.

 

Credit risk

Customers and potential customers are credit checked regularly and given appropriate credit limits based on the financial information available. Credit insurance is also taken out where thought necessary, either due to Company or country risk.

 

Market risk

Market changes, particularly with regard to commodity prices, can affect the financial performance of the Company. Matrix Chemie makes use of the market intelligence and trends noticed that it has at it’s disposal, and also by the use of more widely available trade data and journals published by the industry.

 

 

The company is in excellent health and structed to implement the strategic plans agreed by the board in 2026.

 

The Company is focused on developing a long-term horizon for its products and services. As such, the strategic plan includes ongoing capital investment, a widening of the customer base and expansion of the range of products and services on offer. Several exciting innovations are under development to ensure that the plan is met. Environmental control and health and safety remain at the forefront of all strategic planning initiatives, and the Company continues to invest in these crucial areas.

MATRIX CHEMIE LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Key performance indicators

Matrix Chemie uses KPI’s to monitor it’s financial performance. These include, but are not limited to;

 

Gross Margin %

12.1%

The ration of gross margin to sales, expressed as a % of sales

Debtor Days

65 days

The level of trade debtors & their ration to sales, expressed as a number of days.

Creditor Days

48 days

The level of trade creditors & their ratio to purchases, expressed as a number of days.

Stock days

14 days

The level of stock & their ratio to purchases, expressed as a number of days.

EBITDA

£1,162,812

Earnings before interest, taxation, depreciation and amortisation.

 

On behalf of the board

K Polotnianka
Director
15 June 2026
MATRIX CHEMIE LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

Principal activities

The principal activity of the company continued to be that of international trader and distributor of chemical products for the personal care, home care, water treatment and industrial applications industries.

Results and dividends

The results for the year are set out on page 8.

Ordinary dividends were paid amounting to £564,000. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

K Polotnianka
D M Brooke
C Mullaney
Auditor

Sumer Auditco Limited were appointed as auditor to the company following BHP LLP becoming part of the Sumer Group on 31 December 2025, which required a change in audit firm to comply with applicable regulatory requirements. 

 

In accordance with section 487(2) of the Companies Act 2006, Sumer Auditco Limited are deemed to be reappointed annually.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

On behalf of the board
K Polotnianka
Director
15 June 2026
MATRIX CHEMIE LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 4 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the company website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

MATRIX CHEMIE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MATRIX CHEMIE LIMITED
- 5 -
Opinion

We have audited the financial statements of Matrix Chemie Limited (the 'company') for the year ended 31 December 2025 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

MATRIX CHEMIE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MATRIX CHEMIE LIMITED (CONTINUED)
- 6 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

 

    the engagement partner ensured that the engagement team collectively had the appropriate competence,     capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;

•  we identified the laws and regulations applicable to the company through discussions with management,     and from our commercial knowledge and experience of the sector;

•  we focused on specific laws and regulations which we considered may have a direct material effect on     the financial statements or the operations of the company, including Companies Act 2006, taxation     legislation, data protection, anti-bribery, employment, environments and health and safety legislation;

•  we assessed the extent of compliance with the laws and regulations identified above through making     enquiries of management and inspecting legal correspondence; and

•  identified laws and regulations were communicated within the audit team regularly and the team     remained alert to instances of non-compliance throughout the audit.

 

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

 

•  making enquiries of management as to where they considered there was susceptibility to fraud, their     knowledge of actual, suspected and alleged fraud; and

•  considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and     regulations.

MATRIX CHEMIE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MATRIX CHEMIE LIMITED (CONTINUED)
- 7 -

To address the risk of fraud through management bias and override of controls, we:

 

•  performed analytical procedures to identify any unusual or unexpected relationships;

•  tested journal entries to identify unusual transactions;

•     assessed whether judgements and assumptions made in determining accounting estimates were     indicative of potential bias; and

•  investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

 

•  agreeing financial statement disclosures to underlying supporting documentation; and

•  enquiring of management as to actual and potential litigation and claims.

 

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

 

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Jamie Williams (Senior Statutory Auditor)
For and on behalf of Sumer Auditco Limited, Statutory Auditor
Chartered Accountants
New Chartford House
Centurion Way
Cleckheaton
Bradford
West Yorkshire
BD19 3QB
16 June 2026
MATRIX CHEMIE LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
2025
2024
Notes
£
£
Turnover
3
16,958,898
15,243,020
Cost of sales
(14,904,889)
(13,325,351)
Gross profit
2,054,009
1,917,669
Administrative expenses
(902,343)
(908,242)
Operating profit
4
1,151,666
1,009,427
Interest receivable and similar income
8
10,001
1,930
Interest payable and similar expenses
9
(182)
(1,587)
Profit before taxation
1,161,485
1,009,770
Tax on profit
10
(290,494)
(256,947)
Profit for the financial year
870,991
752,823

The profit and loss account has been prepared on the basis that all operations are continuing operations.

MATRIX CHEMIE LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 9 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
12
15,571
13,644
Current assets
Stocks
13
485,470
674,050
Debtors
14
7,221,614
6,713,966
Cash at bank and in hand
970,846
1,022,863
8,677,930
8,410,879
Creditors: amounts falling due within one year
15
(2,589,485)
(2,627,780)
Net current assets
6,088,445
5,783,099
Total assets less current liabilities
6,104,016
5,796,743
Provisions for liabilities
Deferred tax liability
16
1,835
1,553
(1,835)
(1,553)
Net assets
6,102,181
5,795,190
Capital and reserves
Called up share capital
18
100
100
Profit and loss reserves
6,102,081
5,795,090
Total equity
6,102,181
5,795,190

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 15 June 2026 and are signed on its behalf by:
K Polotnianka
Director
Company registration number 04776118 (England and Wales)
MATRIX CHEMIE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 January 2024
100
5,518,186
5,518,286
Year ended 31 December 2024:
Profit and total comprehensive income
-
752,823
752,823
Dividends
11
-
(475,919)
(475,919)
Balance at 31 December 2024
100
5,795,090
5,795,190
Year ended 31 December 2025:
Profit and total comprehensive income
-
870,991
870,991
Dividends
11
-
(564,000)
(564,000)
Balance at 31 December 2025
100
6,102,081
6,102,181
MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
1
Accounting policies
Company information

Matrix Chemie Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 6 Turnberry Park, Gildersome, Morley, Leeds, LS27 7LE.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of Jeto Holdings Limited. These consolidated financial statements are available from its registered office, Unit 6 Turnberry Park, Gildersome, Morley, Leeds, LS27 7LE.

1.2
Going concern

At the time of approving the financial statements, the directors have trueprepared forecasts and cashflows for a period of at least twelve months from the signing date of these financial statements. The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 12 -
1.3
Revenue

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

The company recognises revenue from the following major sources:

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Sale of goods

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment
10-33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 13 -
1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. The impairment loss is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 14 -
Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

 

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 15 -

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

1.15
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Recoverability of detbors and accrued income

The recoverability of trade receivables is regularly reviewed in the light of the available economic information specific to each receivable, and specific provisions are recognised for balances considered to be irrecoverable.

Stock

Stock is valued at the lower of cost and net realisable value. The directors must ascertain that the provisions included have been properly calculated and reflect the true recoverable stock value as at the period end.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 16 -
3
Turnover and other revenue

An analysis of the company's turnover is as follows:

2025
2024
£
£
Turnover analysed by class of business
Trade and distribution of chemical products
16,958,898
15,243,020
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
2,238,988
1,773,942
Europe
8,659,349
8,661,919
Rest of the World
6,060,561
4,807,159
16,958,898
15,243,020
2025
2024
£
£
Other significant revenue
Interest income
10,001
1,930
4
Operating profit
2025
2024
Operating profit for the year is stated after charging:
£
£
Exchange losses
106,467
58,743
Depreciation of tangible fixed assets
11,146
12,181
Operating lease charges
1,617
2,156
5
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the company
17,150
16,200
For other services
Taxation compliance services
2,950
2,800
All other non-audit services
1,900
-
0
4,850
2,800
MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 17 -
6
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Administrative staff
10
10

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
515,785
541,242
Social security costs
57,813
57,099
Pension costs
44,582
28,358
618,180
626,699
7
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
248,722
279,140
Company pension contributions to defined contribution schemes
36,297
20,528
285,019
299,668

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 2 (2024 - 2).

Remuneration disclosed above include the following amounts paid to the highest paid director:
2025
2024
£
£
Remuneration for qualifying services
124,554
139,656
Company pension contributions to defined contribution schemes
18,149
10,264
8
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
10,001
1,930
MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 18 -
9
Interest payable and similar expenses
2025
2024
£
£
Interest on bank overdrafts and loans
12
39
Other interest on financial liabilities
170
1,548
182
1,587
10
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
290,695
255,394
Adjustments in respect of prior periods
(483)
-
0
Total current tax
290,212
255,394
Deferred tax
Origination and reversal of timing differences
282
1,553
Total tax charge
290,494
256,947

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
1,161,485
1,009,770
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
290,371
252,443
Tax effect of expenses that are not deductible in determining taxable profit
606
59
Change in unrecognised deferred tax assets
-
0
4,445
Adjustments in respect of prior years
(483)
-
0
Taxation charge for the year
290,494
256,947
11
Dividends
2025
2024
£
£
Interim paid
564,000
475,919
MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 19 -
12
Tangible fixed assets
Fixtures, fittings & equipment
£
Cost
At 1 January 2025
161,961
Additions
13,073
At 31 December 2025
175,034
Depreciation and impairment
At 1 January 2025
148,317
Depreciation charged in the year
11,146
At 31 December 2025
159,463
Carrying amount
At 31 December 2025
15,571
At 31 December 2024
13,644
13
Stocks
2025
2024
£
£
Finished goods and goods for resale
485,470
674,050
14
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
3,047,049
2,483,908
Amounts owed by group undertakings
4,030,424
4,030,424
Other debtors
109,586
168,872
Prepayments and accrued income
34,555
30,762
7,221,614
6,713,966

Amounts owed by group undertakings are interest free and repayable on demand.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 20 -
15
Creditors: amounts falling due within one year
2025
2024
Notes
£
£
Other borrowings
22,676
5,853
Trade creditors
1,971,042
2,111,460
Amounts owed to group undertakings
83,567
83,567
Corporation tax
134,743
128,894
Other taxation and social security
17,813
18,161
Other creditors
300,000
200,000
Accruals and deferred income
59,644
79,845
2,589,485
2,627,780

The invoice discounting facility disclosed as other borrowings is secured by a fixed and floating charge over all assets.

16
Deferred taxation

Deferred tax assets and liabilities are offset where the company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:

Liabilities
Liabilities
2025
2024
Balances:
£
£
ACAs
1,835
1,553
2025
Movements in the year:
£
Liability at 1 January 2025
1,553
Charge to profit or loss
282
Liability at 31 December 2025
1,835

The deferred tax liability set out above is expected to reverse within 12 months and relates to accelerated capital allowances that are expected to mature within the same period.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
17
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
44,582
28,358

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

Contributions amounting to £0 (2024: £0) were payable to the scheme and are included in creditors due within one year.

18
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
100
100
100
100
19
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

2025
2024
£
£
Within 1 year
25,030
25,030
Years 2-5
75,090
100,120
100,120
125,150
20
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Accountancy services
2025
2024
£
£
Other related parties
30,134
28,420

 

Other information

The company has taken advantage of the exemption in accordance with Section 33 'Related party disclosures' not to disclose transactions entered into between two or more members of a group, as the company is a wholly owned subsidiary undertaking to which it is party to the transactions.

MATRIX CHEMIE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 22 -
21
Directors' transactions

During the year, one director received £30,134 (2024: £28,420) for the provision of accountancy services to the company.

22
Ultimate controlling party

The immediate parent company is Matrix Chemie Holdings Limited, a company registered in England and Wales.

 

The ultimate parent company is Jeto Holdings Limited. Jeto Holdings Limited prepares group financial statements and copies can be obtained from that company's registered office.

 

K Polotnianka and D M Brooke are the ultimate controlling parties by reference to their shareholdings in Jeto Holdings Limited.

 

2025-12-312025-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2026.100K PolotniankaD M BrookeC Mullaney047761182025-01-012025-12-3104776118bus:Director12025-01-012025-12-3104776118bus:Director22025-01-012025-12-3104776118bus:Director32025-01-012025-12-3104776118bus:RegisteredOffice2025-01-012025-12-31047761182025-12-31047761182024-01-012024-12-3104776118core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3104776118core:RetainedEarningsAccumulatedLosses2025-01-012025-12-31047761182024-12-3104776118core:FurnitureFittings2025-12-3104776118core:FurnitureFittings2024-12-3104776118core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3104776118core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3104776118core:ShareCapital2025-12-3104776118core:ShareCapital2024-12-3104776118core:RetainedEarningsAccumulatedLosses2025-12-3104776118core:RetainedEarningsAccumulatedLosses2024-12-3104776118core:ShareCapital2023-12-3104776118core:RetainedEarningsAccumulatedLosses2023-12-3104776118core:ShareCapitalOrdinaryShareClass12025-12-3104776118core:ShareCapitalOrdinaryShareClass12024-12-3104776118core:FurnitureFittings2025-01-012025-12-3104776118core:UKTax2025-01-012025-12-3104776118core:UKTax2024-01-012024-12-3104776118core:FurnitureFittings2024-12-3104776118core:CurrentFinancialInstruments2025-12-3104776118core:CurrentFinancialInstruments2024-12-3104776118bus:OrdinaryShareClass12025-01-012025-12-3104776118bus:OrdinaryShareClass12025-12-3104776118bus:OrdinaryShareClass12024-12-3104776118core:WithinOneYear2025-12-3104776118core:WithinOneYear2024-12-3104776118core:BetweenTwoFiveYears2025-12-3104776118core:BetweenTwoFiveYears2024-12-3104776118bus:PrivateLimitedCompanyLtd2025-01-012025-12-3104776118bus:FRS1022025-01-012025-12-3104776118bus:Audited2025-01-012025-12-3104776118bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP